Covered recipient · General Payments record
MICHAEL L HADLEY
Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery
General Payments · PY2018–2024
$3,318.81
- Reported across 207 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $277.86 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $59.28 | 3 |
| Amgen Inc. | $43.42 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $26.13 | 1 |
| MIMEDX Group, Inc. | $21.40 | 1 |
| Krystal Biotech Inc | $21.31 | 1 |
| Organon LLC | $20.85 | 1 |
| Regeneron Healthcare Solutions, Inc. | $19.92 | 1 |
| Janssen Pharmaceuticals, Inc | $19.91 | 1 |
| Galderma Laboratories, L.P. | $15.90 | 1 |
| Dermavant Sciences, Inc. | $15.72 | 1 |
| Dynavax Technologies Corporation | $14.02 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.50 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103860309 | CMS |
| ABBVIE INC. | $15.59 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103860311 | CMS |
| ABBVIE INC. | $23.19 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103860313 | CMS |
| Amgen Inc. | $15.56 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117268965 | CMS |
| Amgen Inc. | $14.24 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117268967 | CMS |
| Amgen Inc. | $13.62 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117268969 | CMS |
| Dermavant Sciences, Inc. | $15.72 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127874441 | CMS |
| Dynavax Technologies Corporation | $14.02 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082147119 | CMS |
| Galderma Laboratories, L.P. | $15.90 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145302247 | CMS |
| Janssen Pharmaceuticals, Inc | $19.91 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078218521 | CMS |
| Krystal Biotech Inc | $21.31 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1084810416 | CMS |
| MIMEDX Group, Inc. | $21.40 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140260333 | CMS |
| Novartis Pharmaceuticals Corporation | $26.13 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086885145 | CMS |
| Organon Llc | $20.85 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136198556 | CMS |
| Regeneron Healthcare Solutions, Inc. | $19.92 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114062747 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.